東華大學圖書館 |

語系: 繁體中文

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

In vivo imaging assessment of target...

Chandi, Rupinder K.

Linked to FindBook

Google Book

Amazon

博客來

In vivo imaging assessment of targeted radionnelide therapy of neuroblastoma using small molecule PET probe targeting human norepinephrhe receptor.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	In vivo imaging assessment of targeted radionnelide therapy of neuroblastoma using small molecule PET probe targeting human norepinephrhe receptor./
Author:	Chandi, Rupinder K.
Description:	32 p.
Notes:	Source: Masters Abstracts International, Volume: 52-03.
Contained By:	Masters Abstracts International52-03(E).
Subject:	Health Sciences, Radiology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1547277
ISBN:	9781303486074

In vivo imaging assessment of targeted radionnelide therapy of neuroblastoma using small molecule PET probe targeting human norepinephrhe receptor.
Chandi, Rupinder K.

In vivo imaging assessment of targeted radionnelide therapy of neuroblastoma using small molecule PET probe targeting human norepinephrhe receptor. - 32 p.

Source: Masters Abstracts International, Volume: 52-03.

Thesis (M.S.)--University of California, San Francisco, 2013.

Purpose: Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. Most of neuroblastoma tumors express norepinephrine transporter (NET), which makes metaiodobenzylguanidine (mIBG), an analogue of norepinephrine, an ideal tumor specific agent for therapy, when labeled with I-131. Although drug therapies of neuroblastoma are performed regularly, there is lack of accurate quantitative assessment of tumor response to the therapy. This study was carried out with the objectives: the development of a novel 18F-labeled small molecule-imaging agent that targets the human NET (hNET) receptor, the establishment of a quantitative methodology to assess the therapeutic effect of [131I]mIBG and the establishment of murine xenograft model with a human neuroblastoma cell line that overexpresses hNET for better mIBG uptake would fill an unmet need to further develop treatment for this disease.

ISBN: 9781303486074Subjects--Topical Terms:

1019076
Health Sciences, Radiology.

In vivo imaging assessment of targeted radionnelide therapy of neuroblastoma using small molecule PET probe targeting human norepinephrhe receptor.
LDR:03586nam a2200325 4500 001 1969087
005 20141222143557.5
008 150210s2013 ||||||||||||||||| ||eng d
020 $a 9781303486074
035 $a (MiAaPQ)AAI1547277
035 $a AAI1547277
040 $a MiAaPQ $c MiAaPQ
100 1 $a Chandi, Rupinder K. $3 2106350
245 1 0 $a In vivo imaging assessment of targeted radionnelide therapy of neuroblastoma using small molecule PET probe targeting human norepinephrhe receptor.
300 $a 32 p.
500 $a Source: Masters Abstracts International, Volume: 52-03.
500 $a Adviser: Youngho Seo.
502 $a Thesis (M.S.)--University of California, San Francisco, 2013.
520 $a Purpose: Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. Most of neuroblastoma tumors express norepinephrine transporter (NET), which makes metaiodobenzylguanidine (mIBG), an analogue of norepinephrine, an ideal tumor specific agent for therapy, when labeled with I-131. Although drug therapies of neuroblastoma are performed regularly, there is lack of accurate quantitative assessment of tumor response to the therapy. This study was carried out with the objectives: the development of a novel 18F-labeled small molecule-imaging agent that targets the human NET (hNET) receptor, the establishment of a quantitative methodology to assess the therapeutic effect of [131I]mIBG and the establishment of murine xenograft model with a human neuroblastoma cell line that overexpresses hNET for better mIBG uptake would fill an unmet need to further develop treatment for this disease.
520 $a Methods: In order to enhance mIBG uptake for therapy, luciferase-expressing and hNET-transduced NB1691 (NB1691-luc-hNET) cells were implanted subcutaneously and in the renal capsule of murine xenograft models. Once the tumors reached a defined volume, the mice were injected with the [18F]RP-109, a NET imaging agent and scanned on the microPET/CT instrument. The xenografts were also imaged using bioluminescence to assess the viability of the cells in vivo. The mice were then treated with [[131I]mIBG using an established protocol. Three weeks after the [[131I]mIBG treatment, they were re-imaged on the microPET/CT using [18F]RP-109 as well as by bioluminescence. The PET images were then correlated with the bioluminescence scans as well as tumor volume measurements to assess the utility of the probe for monitoring therapy response of the tumors.
520 $a Results: The novel probe, [18F]RP-109, was successfully prepared and evaluated in neuroblastoma, but no tumor uptake was observed. The treatment of neuroblastoma with [131I]mIBG therapy showed a better response with higher dose of [[131I]mIBG. The therapeutic data obtained from the bioluminescence imaging helps to assess the effectiveness of [131I]mIBG treatment of neuroblastoma model and evaluate the functional status of tumors.
520 $a Conclusion: The NET probe was successfully radiolabelled with fluorine-18 and it did not show any visible uptake in the tumors that overexpress hNET. The [[131I]MIBG therapy study in mouse models using bioluminescence and tumor volume measurement as follow-up showed the effective therapy at 2 mCi level, which was consistent with the estimated tumor dosimetry study performed previously.
590 $a School code: 0034.
650 4 $a Health Sciences, Radiology. $3 1019076
650 4 $a Chemistry, Nuclear. $3 1916260
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0574
690 $a 0738
690 $a 0992
710 2 $a University of California, San Francisco. $b Biomedical Imaging. $3 2106351
773 0 $t Masters Abstracts International $g 52-03(E).
790 $a 0034
791 $a M.S.
792 $a 2013
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1547277